Investigators review the current progress targeting different immune checkpoints in several-lines treatment for TNBC, including programmed death-1/programmed death ligand-1 inhibitors, cytotoxic T-lymphocyte associated antigen-4 inhibitor, and other novel immunotherapeutic approaches.
[Biochimica et Biophysica Acta-Reviews On Cancer]
7992332
{7992332:WHN6NJ4A}
apa
50
1
164753
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/